Text Size: A- A+ Facebook Twitter LinkedIn YouTube

Breaking News

Pledge the Gift of Life

Each year, the lives of thousands of people across the country are saved because someone made the choice to become an organ donor. In April, Allegheny Health Network is honored to celebrate National Donate Life Month and pay tribute to all of those who have bestowed the precious gift of life to another through organ donation. Visit AHNdonate.org to learn more and register to be an organ donor.



Format: 04/23/2014
Format: 04/23/2014


Business Wire: RedPath Integrated Pathology, Inc. Announces Professional Services Agreement with Allegheny General Hospital

Thursday, February 18th, 2010

PITTSBURGH--(BUSINESS WIRE)--RedPath Integrated Pathology, Inc., a molecular diagnostics company dedicated to the effective diagnosis of cancer, has announced that it has entered into a professional services agreement with Allegheny General Hospital (AGH), a leading healthcare provider in southwestern Pennsylvania. According to the agreement, pathologists from AGH and West Penn Hospital (WPH) have been trained at RedPath’s state-of-the-art molecular diagnostics laboratory in the diagnosis of pancreatic cyst fluid specimens collected by endoscopic ultrasound-guided, fine needle aspiration (FNA) and analyzed by RedPath’s proprietary PathFinderTG® mutational profiling technology. With the completion of training, the AGH/ WPH pathologists are certified to sign out PathFinderTG (PFTG) results on specimens sent to RedPath from hospitals, medical centers and endoscopy centers located throughout the United States. Additionally, AGH cytopathologists will also perform cytology analyses on these cyst fluids which will allow RedPath to expand further its test menu for pancreatic cysts.

The service agreement will result in several benefits to physicians faced with the challenges of managing patients diagnosed with pancreatic cysts on CT or MRI scans.

  • RedPath is the only clinical laboratory that can provide results from a full menu of molecular (PFTG) and non-molecular tests (CEA, amylase, and cytology) from low-volume pancreatic cyst aspirates.
  • Having all laboratory, cytology, and molecular results in one place for the review by the pathologists at the time of sign-out of these complex cases provides the best opportunity for full integration of all results, a vital step in providing the most accurate diagnosis possible.
  • Combining AGH nationally-recognized cytopathologists with RedPath’s molecular mutational profiling expertise creates a unique opportunity to provide insights into why some pancreatic cystic lesions progress to cancer while many others remain benign.
  • This relationship also sets the stage for collaborative studies in other challenging areas of pathology and oncology such as using mutational profiling to determine the relatedness of multiple tumors.


Jan F. Silverman, M.D., Chairman of AGH and WPH Departments of Pathology and Laboratory Medicine commented, “The combination of cytopathology analysis with the molecular diagnostics of pancreatic cyst fluid will allow a better understanding of the nature of the pancreatic cyst and its potential malignant behavior. The pathologists at Allegheny General Hospital and West Penn Hospital look forward to combining our expertise with the state-of-the-art molecular diagnostics offered by RedPath Integrated Pathology.”

To read more, visit the BusinessWire website.

West Penn Allegheny Health System
Tell us who you are:

What areas do you use on our website?*
(select more than one if it applies)

Did you find what you were looking for?

Would you refer others to our website?

Can we contact you for future questions?

CAPTCHA math question:* 1 + 6 =

Thank you for completing the West Penn Allegheny Health System website survey.
We value your feedback and comments.